Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics


Axsome Therapeutics, Inc. (AXSM)

Today's Latest Price: $74.48 USD

0.23 (0.31%)

Updated Jun 4 6:55pm

Add AXSM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AXSM Daily Price Range
AXSM 52-Week Price Range

AXSM Stock Price Chart More Charts


AXSM Price/Volume Stats

Current price $74.48 52-week high $109.94
Prev. close $74.25 52-week low $13.64
Day low $73.44 Volume 432,500
Day high $76.28 Avg. volume 887,342
50-day MA $75.12 Dividend yield N/A
200-day MA $59.13 Market Cap 2.76B

Axsome Therapeutics, Inc. (AXSM) Company Bio


Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.


AXSM Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AXSM Latest Social Stream


Loading social stream, please wait...

View Full AXSM Social Stream

Latest AXSM News From Around the Web

Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.

Edited Transcript of AXSM earnings conference call or presentation 8-May-20 12:00pm GMT

Q1 2020 Axsome Therapeutics Inc Earnings Call

Yahoo | June 4, 2020

Axsome Therapeutics to Present at Upcoming Investor Conferences

Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat. A live webcast and archive of the William Blair event can be viewed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at www.axsome.com. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.

Yahoo | June 4, 2020

Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3 trial of AXS-05 in major depressive disorder (MDD) will be presented in oral and poster sessions at the 2020 Annual Meeting of the American Society for Clinical Psychopharmacology (ASCP), to be held virtually, May 29-30. AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.

Yahoo | May 29, 2020

Is Axsome Therapeutics a Buy?

The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?

Yahoo | May 26, 2020

Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually

Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a virtual-only meeting format due to continued public health concerns resulting from the COVID-19 pandemic, government-recommended and required limits on public gatherings, and to protect the health and safety of the Company’s stockholders, directors, and employees. Stockholders will not be able to attend the Annual Meeting in person. The Company’s stockholders as of the close of business on April 9, 2020 (the “Record Date”) can join the live virtual meeting.

Yahoo | May 26, 2020

Read More 'AXSM' Stories Here

AXSM Price Returns

1-mo -17.57%
3-mo -11.02%
6-mo 63.94%
1-year 245.13%
3-year 1,694.70%
5-year N/A
YTD -27.94%
2019 3,565.25%
2018 -49.64%
2017 -17.04%
2016 -27.18%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8533 seconds.